BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh R, Bansal Y, Medhi B, Kuhad A. Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol 2019;844:231-40. [PMID: 30529195 DOI: 10.1016/j.ejphar.2018.12.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Rotella F, Cassioli E, Calderani E, Lazzeretti L, Ragghianti B, Ricca V, Mannucci E. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol 2020;32:56-65. [PMID: 31917068 DOI: 10.1016/j.euroneuro.2019.12.118] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Hidese S, Ota M, Matsuo J, Ishida I, Yokota Y, Hattori K, Yomogida Y, Kunugi H. Association between obesity and white matter microstructure impairments in patients with schizophrenia: A whole-brain magnetic resonance imaging study. Schizophr Res 2021;230:108-10. [PMID: 32771309 DOI: 10.1016/j.schres.2020.07.009] [Reference Citation Analysis]
3 Rice J, Ramtekkar U. Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics. Med Sci (Basel) 2020;8:E34. [PMID: 32824428 DOI: 10.3390/medsci8030034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zwickl H, Zwickl-Traxler E, Pecherstorfer M. Is Neuronal Histamine Signaling Involved in Cancer Cachexia? Implications and Perspectives. Front Oncol 2019;9:1409. [PMID: 31921666 DOI: 10.3389/fonc.2019.01409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Smith E, Singh R, Lee J, Colucci L, Graff-Guerrero A, Remington G, Hahn M, Agarwal SM. Adiposity in schizophrenia: A systematic review and meta-analysis. Acta Psychiatr Scand 2021;144:524-36. [PMID: 34458979 DOI: 10.1111/acps.13365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
6 Li NN, Xiang SY, Huang XX, Li YT, Luo C, Ju PJ, Xu YF, Chen JH. Network pharmacology-based exploration of therapeutic mechanism of Liu-Yu-Tang in atypical antipsychotic drug-induced metabolic syndrome. Comput Biol Med 2021;134:104452. [PMID: 33984751 DOI: 10.1016/j.compbiomed.2021.104452] [Reference Citation Analysis]
7 Dubath C, Gholam-Rezaee M, Sjaarda J, Levier A, Saigi-Morgui N, Delacrétaz A, Glatard A, Panczak R, Correll CU, Solida A, Plessen KJ, von Gunten A, Kutalik Z, Conus P, Eap CB. Socio-economic position as a moderator of cardiometabolic outcomes in patients receiving psychotropic treatment associated with weight gain: results from a prospective 12-month inception cohort study and a large population-based cohort. Transl Psychiatry 2021;11:360. [PMID: 34226496 DOI: 10.1038/s41398-021-01482-9] [Reference Citation Analysis]
8 Endomba FT, Tankeu AT, Nkeck JR, Tochie JN. Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain? Lipids Health Dis 2020;19:22. [PMID: 32033608 DOI: 10.1186/s12944-020-01203-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
9 Landau Z, Pinhas-hamiel O. Attention Deficit/Hyperactivity, the Metabolic Syndrome, and Type 2 Diabetes. Curr Diab Rep 2019;19. [DOI: 10.1007/s11892-019-1174-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
10 Dubath C, Piras M, Gholam M, Laaboub N, Grosu C, Sentissi O, Gamma F, Solida A, von Gunten A, Conus P, Eap CB. Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study. Pharmacopsychiatry 2021. [PMID: 34388836 DOI: 10.1055/a-1525-2820] [Reference Citation Analysis]
11 Singh R, Bansal Y, Sodhi RK, Khare P, Bishnoi M, Kondepudi KK, Medhi B, Kuhad A. Role of TRPV1/TRPV3 channels in olanzapine-induced metabolic alteration: Possible involvement in hypothalamic energy-sensing, appetite regulation, inflammation and mesolimbic pathway. Toxicol Appl Pharmacol 2020;402:115124. [PMID: 32652086 DOI: 10.1016/j.taap.2020.115124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Verhaegen AA, Van Gaal LF. Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update. Curr Obes Rep 2021;10:1-13. [PMID: 33400222 DOI: 10.1007/s13679-020-00419-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Liu C, Kang D, Xiao J, Huang Y, Peng X, Wang W, Xie P, Yang Y, Zhao J, Wu R. Dietary fiber and probiotics for the treatment of atypical antipsychotic-induced metabolic side effects: study protocol for a randomized, double-blind, placebo-controlled trial. Trials 2021;22:159. [PMID: 33622382 DOI: 10.1186/s13063-021-05123-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Singh R, Stogios N, Smith E, Lee J, Maksyutynsk K, Au E, Wright DC, De Palma G, Graff-guerrero A, Gerretsen P, Müller DJ, Remington G, Hahn M, Agarwal SM. Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. Therapeutic Advances in Psychopharmacology 2022;12:204512532210965. [DOI: 10.1177/20451253221096525] [Reference Citation Analysis]
15 Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. PLoS One 2021;16:e0244944. [PMID: 33596211 DOI: 10.1371/journal.pone.0244944] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wu C, Wang Y, Yang F, Shi W, Wang Z, He L, He Y, Shen J. Synthesis and Biological Evaluation of Five-Atom-Linker-Based Arylpiperazine Derivatives with an Atypical Antipsychotic Profile. ChemMedChem 2019;14:2042-51. [PMID: 31746558 DOI: 10.1002/cmdc.201900439] [Reference Citation Analysis]
17 Singh R, Bansal Y, Sodhi RK, Saroj P, Medhi B, Kuhad A. Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor. Toxicology and Applied Pharmacology 2019;378:114643. [DOI: 10.1016/j.taap.2019.114643] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
18 Lis M, Stańczykiewicz B, Liśkiewicz P, Misiak B. Impaired hormonal regulation of appetite in schizophrenia: A narrative review dissecting intrinsic mechanisms and the effects of antipsychotics. Psychoneuroendocrinology 2020;119:104744. [DOI: 10.1016/j.psyneuen.2020.104744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
19 Sodhi RK, Singh R, Bansal Y, Bishnoi M, Parhar I, Kuhad A, Soga T. Intersections in Neuropsychiatric and Metabolic Disorders: Possible Role of TRPA1 Channels. Front Endocrinol (Lausanne) 2021;12:771575. [PMID: 34912298 DOI: 10.3389/fendo.2021.771575] [Reference Citation Analysis]
20 Marteene W, Winckel K, Hollingworth S, Kisely S, Gallagher E, Hahn M, Ebdrup BH, Firth J, Siskind D. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf 2019;18:1149-60. [PMID: 31564170 DOI: 10.1080/14740338.2019.1674809] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
21 Lee TH, Cheng KK, Hoo RL, Siu PM, Yau SY. The Novel Perspectives of Adipokines on Brain Health. Int J Mol Sci. 2019;20:5638. [PMID: 31718027 DOI: 10.3390/ijms20225638] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
22 Fève B, Scheen AJ. When therapeutic drugs lead to diabetes. Diabetologia 2022. [PMID: 35244742 DOI: 10.1007/s00125-022-05666-w] [Reference Citation Analysis]
23 Alvarez-Herrera S, Escamilla R, Medina-Contreras O, Saracco R, Flores Y, Hurtado-Alvarado G, Maldonado-García JL, Becerril-Villanueva E, Pérez-Sánchez G, Pavón L. Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Front Endocrinol (Lausanne) 2020;11:195. [PMID: 32373066 DOI: 10.3389/fendo.2020.00195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Singh R, Bansal Y, Sodhi RK, Singh DP, Bishnoi M, Kondepudi KK, Medhi B, Kuhad A. Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. Life Sci 2020;247:117442. [PMID: 32081663 DOI: 10.1016/j.lfs.2020.117442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]